Riskpilot← Back to searchSign inGet full accessIMMUNOR AS
ASActiveOrg 914405920Gaustadalléen 21, 0349 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20140 employeeswww.immunor.com
Revenue 2024
NOK 0
EBITDA margin
—
-671% vs 2023
Equity ratio
-26.2%
Financial strength
Net profit 2024
NOK -1,4M
-234% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -1,3M | -671% |
| Net profit | NOK -1,4M | -234% |
| Total assets | NOK 404K | +659% |
| Equity | NOK -106K | +97% |
| Employees | 0 | — |
Legal name
IMMUNOR AS
Org number
914405920
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
13. november 2014
Share capital
NOK 138 426
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Handel, rådgivning, bioteknologisk forskning og utvikling, eie og forvalte aksjer og verdipapirer, delta i andre foretak og alt som har forbindelse med dette.
Address
Gaustadalléen 21, 0349 Oslo
Website
www.immunor.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 305 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −137 | −74 | −13 | −0 | −0 |
| EBITDA | −24 | −44 | −60 | −22 | −222 | −1 221 | −262 | −498 | −172 | −1 328 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −24 | −44 | −60 | −22 | −222 | −1 221 | −262 | −498 | −172 | −1 328 |
| Net financials | −0 | −12 | −21 | 0 | −0 | 0 | 39 | −414 | −245 | −66 |
| Profit before tax | −24 | −57 | −81 | −22 | −222 | −1 220 | −223 | −912 | −418 | −1 395 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −24 | −57 | −81 | −22 | −222 | −1 220 | −223 | −912 | −418 | −1 395 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 6 | 24 | 54 | 58 | 125 | 280 | 177 | 44 | 53 | 404 |
| Equity | 0 | −56 | −137 | −159 | −380 | −1 601 | −1 824 | −2 736 | −3 127 | −106 |
| Long-term debt | 0 | 70 | 177 | 207 | 392 | 1 102 | 1 752 | 2 205 | 2 470 | 350 |
| Short-term debt | 6 | 11 | 14 | 10 | 114 | 779 | 249 | 575 | 711 | 159 |
| Total debt | 6 | 81 | 190 | 217 | 505 | 1 881 | 2 001 | 2 780 | 3 181 | 510 |
EBITDA margin
-132831600.0%
This company
15.8%
Market median
-840706429% vs market
20152024
Equity ratio
-26.2%
This company
38.2%
Market median
-169% vs market
20152024
Return on equity
-139473600.0%
This company
18.4%
Market median
-758008796% vs market
20152024
Net profit margin
-139473600.0%
This company
8.1%
Market median
-1721896396% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
4.81×
This company
0.62×
Market median
-676% vs market
20152024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2014-10-22 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AS Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2016 | — | — | |
| Chairman | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Schjøsus Invest As | Company | 33.0% | 33.0% | 2024 |
Kag As | Company | 30.8% | 30.8% | 2024 |
Cecilia Nauclr | Company | 13.1% | 13.1% | 2024 |
Cecilia Nauclér | Company | 11.1% | 11.1% | 2023 |
Gwythian Prins | Company | 6.7% | 6.7% | 2023 |
Wivel Invest As | Company | 3.3% | 3.3% | 2024 |
A A Holding As | Company | 3.0% | 3.0% | 2024 |
Grafo As | Company | 2.1% | 2.1% | 2024 |
Pharmavizer Ab | Company | 1.9% | 1.9% | 2024 |
Endera As | Company | 1.4% | 1.4% | 2024 |
Js Holding As | Company | 1.4% | 1.4% | 2024 |
Jahatt As | Company | 1.2% | 1.2% | 2024 |
Jakob Hatteland Holding As | Company | 1.1% | 1.1% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
IMMUNOR AS 
PERIOVACX ASBoard members of IMMUNOR AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andres Schjønhaug Susrud | Chief Executive Officer | 0 companies |
| Dag Arne Wivelstad | Board of Directors | 0 companies |
| Aslak Aslaksen | Board of Directors | 0 companies |
| Birger Sørensen | Chairman | 0 companies |